Digital Therapeutics for GAD Market Report 2034

Report Description

This report is updated with the latest market data and insights as of June 2026. Base year: 2025  |  Forecast period: 2026-2034

Digital Therapeutics Generalized Anxiety Disorder Market Outlook

According to our latest research, the global Digital Therapeutics for Generalized Anxiety Disorder market size reached USD 1.79 billion in 2025, reflecting a robust adoption curve across both developed and emerging economies. The market is expected to grow at a CAGR of 23.8% from 2026 to 2034, reaching an estimated value of USD 12.8 billion by the end of the forecast period. This strong growth trajectory is primarily driven by the rising prevalence of anxiety disorders, technological advancements in digital health solutions, and increasing acceptance of non-pharmacological interventions for mental health management, as per our latest research findings. The broader digital therapeutics anxiety segment provides important context for understanding how GAD-specific solutions fit within the wider mental health technology landscape.

Get Free Sample Report

One of the primary growth factors propelling the expansion of the Digital Therapeutics for Generalized Anxiety Disorder market is the escalating global burden of anxiety disorders, particularly Generalized Anxiety Disorder (GAD). The World Health Organization estimates that anxiety disorders affect over 300 million people worldwide, with GAD representing a significant proportion of these cases. Traditional treatment modalities, such as pharmacotherapy and face-to-face psychotherapy, often face barriers related to accessibility, cost, and social stigma. Digital therapeutics offer a scalable, cost-effective, and stigma-free alternative, enabling individuals to access evidence-based interventions from the comfort of their homes. The increasing awareness about mental health, de-stigmatization efforts, and the integration of digital health tools into mainstream healthcare are further accelerating the adoption of digital therapeutics for GAD. As of 2025, over 60% of new users in North America report discovering digital therapeutic solutions through employer or insurer benefit programs, underscoring the growing institutional appetite for these interventions.

Technological advancements play a pivotal role in shaping the Digital Therapeutics for Generalized Anxiety Disorder market. The proliferation of smartphones, wearables, and high-speed internet connectivity has created a fertile environment for the development and distribution of sophisticated digital therapeutic solutions. Artificial intelligence, machine learning, and data analytics are being leveraged to personalize interventions, monitor patient progress in real time, and provide adaptive feedback, thereby enhancing treatment efficacy and user engagement. Moreover, regulatory bodies such as the FDA and EMA are increasingly recognizing and approving digital therapeutics as legitimate medical interventions, which is bolstering clinician and patient trust in these solutions. Strategic collaborations between technology companies, healthcare providers, and payers are also facilitating wider adoption and reimbursement of digital therapeutics for anxiety disorders.

Another significant growth driver is the shift in healthcare delivery models towards patient-centric, value-based care. Digital therapeutics for GAD align perfectly with these trends by offering measurable outcomes, remote monitoring, and seamless integration with existing healthcare infrastructure. Employers and payers are increasingly recognizing the economic and productivity benefits of addressing mental health issues proactively, leading to the incorporation of digital therapeutic solutions into employee wellness programs and insurance packages. This not only expands the addressable market but also ensures sustained engagement and adherence among users. The COVID-19 pandemic laid critical groundwork that has continued into 2025, as the precedent for telehealth and digital mental health services established during lockdown years has become a permanent feature of mainstream healthcare delivery globally.

Regionally, North America dominates the Digital Therapeutics for Generalized Anxiety Disorder market, accounting for the largest revenue share in 2025. This leadership is attributed to high digital literacy, favorable reimbursement policies, and a robust ecosystem of digital health innovators. Europe follows closely, driven by progressive regulatory frameworks and increasing investments in mental health infrastructure. The Asia Pacific region, while representing approximately 18.5% of the global market in 2025, is poised for the fastest growth during the forecast period, fueled by rising mental health awareness, expanding smartphone penetration, and supportive government initiatives. Latin America and the Middle East & Africa are gradually emerging as promising markets, with growing investments in digital health and shifting attitudes towards mental health care.

Product Type Analysis

The Product Type segment of the Digital Therapeutics for Generalized Anxiety Disorder market is categorized into Software Applications, Devices, and Platforms. Software applications currently represent the largest share at approximately 58.5% of the market in 2025, driven by the widespread availability of mobile apps and web-based solutions designed to deliver cognitive behavioral therapy, mindfulness exercises, and symptom tracking. These applications are popular due to their convenience, cost-effectiveness, and ability to provide personalized interventions. Many leading digital therapeutics providers have invested heavily in developing user-friendly, evidence-based apps that cater to diverse patient needs, thereby expanding their reach and impact. As the market matures through the 2026-2034 forecast period, software applications are expected to maintain their dominance, supported by continuous innovation and regulatory approvals.

Get Free Sample Report

Devices, including wearables and connected sensors, are gaining traction as complementary tools in managing Generalized Anxiety Disorder, accounting for approximately 18.5% of the market in 2025. These devices enable real-time monitoring of physiological parameters such as heart rate variability, sleep patterns, and stress levels, providing valuable data that can inform personalized treatment plans. Integration of biofeedback and digital coaching features enhances user engagement and adherence, making devices an attractive option for both patients and healthcare providers. The devices segment is expected to witness significant growth through 2034 as technology advances, costs decrease, and consumer interest in continuous self-monitoring intensifies. This convergence of hardware and therapeutic software is also creating synergies with digital therapeutics developed for co-occurring substance use conditions, where biometric monitoring plays a similarly important role.

Platforms, which serve as comprehensive ecosystems integrating multiple digital therapeutic tools, account for approximately 23.0% of the market in 2025 and are emerging as a critical component of the overall landscape. These platforms offer seamless interoperability between software applications, devices, and healthcare systems, enabling holistic management of Generalized Anxiety Disorder. They often include features such as secure data sharing, remote consultations, and population health analytics, making them valuable for healthcare providers, payers, and employers. The growing emphasis on interoperability and data-driven care is expected to drive the adoption of integrated platforms, particularly in institutional and enterprise settings, throughout the forecast period.

The competitive landscape within the Product Type segment is characterized by rapid innovation and strategic partnerships. Leading players are investing in research and development to enhance the effectiveness, user experience, and clinical validation of their offerings. Collaborations between technology companies, academic institutions, and healthcare organizations are fostering the development of next-generation digital therapeutic solutions that leverage artificial intelligence, virtual reality, and gamification. As competition intensifies through 2034, differentiation will increasingly hinge on clinical outcomes, user engagement metrics, and integration capabilities with electronic health records and payer systems.

Looking ahead, the Product Type segment is poised for continued evolution as new technologies and therapeutic modalities emerge. The convergence of software applications, devices, and platforms is expected to create a more seamless and integrated user experience, driving higher adoption rates and improved clinical outcomes. Regulatory clarity and reimbursement support will be critical in sustaining growth and ensuring that innovative digital therapeutic products can reach a broader patient population across all regions through the end of the forecast period in 2034.

Report Scope

Therapy Type Analysis

The Therapy Type segment encompasses Cognitive Behavioral Therapy (CBT), Mindfulness-Based Therapy, Acceptance and Commitment Therapy (ACT), and other modalities. Among these, Cognitive Behavioral Therapy stands out as the most widely adopted and clinically validated approach for managing Generalized Anxiety Disorder. Digital CBT programs are supported by a robust body of evidence demonstrating their efficacy in reducing anxiety symptoms and improving functional outcomes. The scalability and accessibility of digital CBT make it a preferred choice for healthcare providers and patients alike, particularly in regions with limited access to traditional psychotherapy services. As of 2025, digital CBT represents the single largest therapy type sub-segment, and its dominance is expected to persist through 2034 as clinical guidelines increasingly endorse technology-delivered CBT as a first-line option.

Mindfulness-Based Therapy is gaining momentum as an effective intervention for Generalized Anxiety Disorder, particularly among individuals seeking holistic and non-pharmacological approaches to mental health. Digital mindfulness programs leverage guided meditation, breathing exercises, and relaxation techniques to help users manage stress and anxiety. The popularity of mindfulness-based apps has surged in recent years, driven by growing consumer interest in wellness and self-care. Companies such as Calm and Headspace Health have built substantial user bases that are now being channeled into clinically validated therapeutic applications, blurring the line between consumer wellness and regulated digital therapeutics. Clinical studies have confirmed that digital mindfulness interventions can produce significant reductions in anxiety symptoms, further validating their role in the therapeutic landscape through the forecast period.

Acceptance and Commitment Therapy (ACT) is another emerging modality within the digital therapeutics market for GAD. ACT focuses on helping individuals accept their thoughts and feelings rather than trying to control or avoid them, while committing to behavior changes aligned with personal values. Digital ACT programs offer interactive exercises, educational content, and real-time feedback, making them accessible and engaging for users. The evidence base for digital ACT has been growing steadily and, as of 2025, several platforms now offer ACT as a standalone module or integrated component within broader mental health programs. The parallels between ACT-based approaches for GAD and those developed for digital therapeutic applications targeting depression are notable, given the high comorbidity between these conditions.

Other therapeutic modalities, such as exposure therapy, psychoeducation, and relaxation training, are also being incorporated into digital therapeutic solutions for Generalized Anxiety Disorder. These approaches are often delivered as standalone modules or as part of comprehensive treatment programs, allowing for personalized and flexible care. The ability to tailor interventions to individual preferences and needs is a key advantage of digital therapeutics, enhancing user satisfaction and long-term adherence.

The Therapy Type segment is expected to witness ongoing innovation and diversification throughout the 2026-2034 forecast period as new evidence emerges and user preferences evolve. Hybrid approaches that combine multiple therapeutic modalities are likely to gain traction, offering synergistic benefits and addressing the complex, multifaceted nature of Generalized Anxiety Disorder. Collaboration between clinicians, researchers, and technology developers will be essential in advancing the science and practice of digital therapeutics for GAD.

Age Group Analysis

The Age Group segment is divided into Children & Adolescents, Adults, and Geriatric populations, each with distinct needs and preferences when it comes to digital therapeutics for Generalized Anxiety Disorder. Adults currently represent the largest user base in 2025, reflecting the high prevalence of GAD in this demographic and the widespread adoption of digital health technologies among working-age individuals. Digital therapeutic solutions for adults often emphasize self-management, goal setting, and real-time feedback, catering to the busy lifestyles and autonomy of this group. Employer-sponsored adoption is particularly driving adult usage, as corporations increasingly integrate mental health platforms into comprehensive benefits packages.

Children and Adolescents constitute a rapidly growing segment within the Digital Therapeutics for Generalized Anxiety Disorder market. The rising incidence of anxiety disorders among young people, particularly in the aftermath of pandemic-era disruptions to education and social development, has created significant demand for age-appropriate digital therapeutic solutions. These programs incorporate gamification, interactive storytelling, and parental involvement to enhance engagement and effectiveness. Regulatory agencies and educational institutions are increasingly recognizing the value of digital therapeutics in supporting the mental health of children and adolescents, leading to greater adoption in schools and pediatric healthcare settings during 2025 and beyond. Companies such as Limbix have positioned themselves specifically within this demographic, developing clinically validated solutions for adolescent anxiety management.

The Geriatric population, while currently representing a smaller share of the market, is expected to witness substantial growth between 2026 and 2034. Older adults face unique challenges in accessing traditional mental health services, including mobility limitations, stigma, and complex comorbidities. Digital therapeutics offer a convenient and discreet alternative, enabling seniors to manage anxiety symptoms from home. Solutions tailored for the geriatric population feature simplified interfaces, larger text, and voice-guided instructions to accommodate age-related sensory and cognitive changes. As the global population ages and digital literacy among older adults improves, demand for senior-friendly digital therapeutic solutions is anticipated to rise significantly, representing a compelling growth opportunity for market participants.

Each age group presents unique opportunities and challenges for digital therapeutics providers. Customization of content, interface design, and engagement strategies is essential to ensure that interventions are both effective and user-friendly across diverse demographic segments. Collaboration with caregivers, educators, and healthcare professionals is particularly important when designing solutions for children, adolescents, and older adults, where third-party involvement in care is common.

The Age Group segment is poised for dynamic growth as digital therapeutics become increasingly embedded in everyday life through the forecast period. Advances in user experience design, accessibility features, and age-specific clinical content will be critical in expanding the reach and impact of digital therapeutic solutions for Generalized Anxiety Disorder across all demographic groups by 2034.

Distribution Channel Analysis

The Distribution Channel segment includes Healthcare Providers, Online Platforms, Pharmacies, and Others, each playing a vital role in the dissemination of digital therapeutics for Generalized Anxiety Disorder. Healthcare providers remain a primary distribution channel in 2025, leveraging their trusted relationships with patients to recommend and prescribe digital therapeutic solutions. Integration with electronic health records and telemedicine platforms facilitates seamless access and monitoring, enhancing the overall quality of care. Healthcare providers are increasingly incorporating digital therapeutics into routine clinical practice, supported by growing clinical evidence, clearer regulatory frameworks, and expanding reimbursement options across major markets.

Online platforms have emerged as a dominant force in the distribution of digital therapeutics, offering direct-to-consumer access and unparalleled convenience. These platforms provide users with a wide range of digital therapeutic apps and programs, often accompanied by educational resources, community support, and personalized recommendations. The rise of app stores, telehealth services, and digital health marketplaces has democratized access to evidence-based interventions, enabling individuals to seek help privately and on their own terms. Online platforms are particularly popular among younger, tech-savvy users and those in remote or underserved areas, and their importance as a distribution channel is expected to grow further through the 2026-2034 forecast period.

Pharmacies are increasingly playing a role in the distribution of digital therapeutics, particularly as these solutions gain regulatory approval and become eligible for reimbursement. As of 2025, several major pharmacy chains in North America and Europe have begun offering digital therapeutic products alongside traditional medications, providing patients with a holistic approach to managing Generalized Anxiety Disorder. Pharmacists are well-positioned to educate consumers about the benefits of digital therapeutics, support adherence, and facilitate integration with other treatments. The inclusion of digital therapeutics in pharmacy formularies and health insurance plans is expected to drive further adoption across the forecast period.

Other distribution channels, such as employer wellness programs, insurance providers, and community organizations, are contributing meaningfully to the expansion of the market. Employers are increasingly offering digital therapeutic solutions as part of comprehensive mental health and wellness initiatives, recognizing the impact of anxiety disorders on productivity and employee well-being. Insurance providers are exploring innovative reimbursement models to support broader adoption, while community organizations are leveraging these tools to reach vulnerable and underserved populations in both urban and rural settings.

The Distribution Channel segment is characterized by increasing convergence and collaboration among stakeholders. Partnerships between digital therapeutics developers, healthcare providers, pharmacies, and online platforms are enabling more integrated and accessible care pathways. As the market evolves through 2034, the focus will shift towards optimizing omnichannel distribution strategies that maximize patient reach, sustained engagement, and measurable clinical outcomes.

End-User Analysis

The End-User segment encompasses Patients, Healthcare Providers, Payers, and Employers, each with distinct roles and interests in the adoption and utilization of digital therapeutics for Generalized Anxiety Disorder. Patients are the primary end-users, seeking accessible, effective, and stigma-free solutions to manage anxiety symptoms. The convenience, privacy, and personalization offered by digital therapeutics resonate strongly with patients in 2025, particularly those who face barriers to traditional care such as geographic distance, high out-of-pocket costs, or cultural stigma. User engagement and satisfaction are critical determinants of success in this segment, driving ongoing innovation in content design, adaptive algorithms, and behavioral engagement techniques.

Healthcare providers are key stakeholders in the digital therapeutics ecosystem, responsible for recommending, prescribing, and monitoring the use of these solutions. Providers value digital therapeutics for their ability to extend the reach of care, support remote monitoring, and generate actionable data on patient progress between clinical appointments. Integration with clinical workflows and electronic health records is essential to ensure seamless adoption and effective care coordination. As clinical evidence and regulatory support for digital therapeutics have strengthened through 2025, providers are more frequently incorporating these tools into standard treatment protocols for GAD.

Payers, including insurance companies and government health programs, play a critical role in driving the adoption of digital therapeutics by determining coverage and reimbursement policies. The ability of digital therapeutics to deliver measurable outcomes, reduce total healthcare costs, and improve population health aligns directly with payer priorities, making these solutions attractive for inclusion in benefit packages. As of 2025, an increasing number of commercial insurers and national health systems in Europe have introduced coverage for select digital therapeutic products, with further expansion anticipated through the forecast period. Innovative outcome-based pricing models are emerging as a key enabler of market growth in this segment.

Employers are increasingly recognizing the value of digital therapeutics in supporting employee mental health and well-being. Anxiety disorders are a leading cause of absenteeism, presenteeism, and reduced workforce productivity globally. By offering digital therapeutic solutions as part of employee wellness programs, employers can proactively address mental health challenges, enhance workforce resilience, and reduce downstream healthcare costs. In 2025, large self-insured employers represent one of the fastest-growing buyer segments for digital mental health platforms, with companies such as Spring Health, Lyra Health, and Modern Health capturing significant enterprise contracts across North America and Europe.

The End-User segment is characterized by diverse needs, preferences, and adoption drivers. Successful market expansion through 2034 will depend on the ability to address these unique requirements through tailored solutions, effective stakeholder engagement, and robust evidence of both clinical and economic value. Cross-sector partnerships and integrated care models will be essential in maximizing the long-term impact of digital therapeutics for Generalized Anxiety Disorder.

Opportunities & Threats

The Digital Therapeutics for Generalized Anxiety Disorder market presents a wealth of opportunities for stakeholders across the healthcare value chain as the industry moves through its 2026-2034 forecast period. One of the most significant opportunities lies in the expansion of access to mental health care, particularly in underserved and remote regions where traditional services are scarce. Digital therapeutics can bridge the gap by providing scalable, cost-effective, and evidence-based interventions that transcend geographical and socioeconomic barriers. The continued normalization of telehealth and remote care delivery, established firmly by 2025, has created a durable favorable environment for digital therapeutic adoption. Additionally, rapid advancements in artificial intelligence, large language models, and real-time data analytics are enabling the development of highly personalized and adaptive interventions that significantly enhance user engagement and treatment efficacy across all major therapy modalities.

Another major opportunity lies in the integration of digital therapeutics with existing healthcare systems and care pathways. Seamless interoperability with electronic health records, telemedicine platforms, and population health management tools can enhance care coordination, data-driven clinical decision-making, and outcome measurement. Partnerships between digital therapeutics developers, healthcare providers, payers, and employers are facilitating the creation of comprehensive mental health ecosystems that address the needs of diverse patient populations. The emergence of value-based care models and outcome-based reimbursement is further incentivizing adoption, as payers and providers seek to improve quality of care while controlling escalating mental health treatment costs. The potential for international expansion is also substantial, with emerging markets in Asia Pacific, Latin America, and the Middle East & Africa offering significant untapped growth opportunities through 2034.

Despite these opportunities, the market faces several threats and restraining factors that could impede growth. Data privacy and cybersecurity concerns remain a top priority in 2025, as digital therapeutics involve the continuous collection and transmission of sensitive personal health information. Ensuring compliance with evolving data protection regulations, including GDPR in Europe and HIPAA in the United States, is essential to maintain user trust and avoid legal and reputational liabilities. Variability in regulatory requirements across regions creates challenges for global market entry and product scalability. Limited digital literacy and technology access among certain population segments, particularly older adults and those in low-resource settings, may also constrain adoption. Reimbursement fragmentation, resistance from segments of the traditional healthcare community, and the ongoing requirement for robust clinical evidence generation are additional factors that could moderate the pace of market growth. Addressing these threats will require sustained investment in technology infrastructure, health education, regulatory engagement, and stakeholder collaboration across the industry.

Regional Outlook

North America remains the largest regional market for Digital Therapeutics for Generalized Anxiety Disorder, capturing approximately 41.5% of the global market share in 2025, equivalent to around USD 743 million. The region's leadership is underpinned by high digital health adoption rates, supportive and evolving regulatory policies, and a strong ecosystem of technology innovators and healthcare providers. The United States continues to see significant venture capital investment in digital mental health startups, robust real-world evidence generation, and expanding reimbursement frameworks that are accelerating market growth. Canada is also making strides in integrating digital therapeutics into its public health system, further contributing to regional expansion, and the region is projected to maintain its leading position through 2034.

Get Free Sample Report

Europe follows as the second-largest market, accounting for approximately 30.5% of global revenues, or about USD 546 million in 2025. The region benefits from progressive regulatory frameworks, widespread mental health awareness, and increasing government investments in digital health infrastructure. Countries such as the United Kingdom, Germany, and the Nordic nations are at the forefront of digital therapeutics adoption, with several national health systems incorporating digital mental health solutions into standard care pathways. Germany's DiGA (Digitale Gesundheitsanwendungen) fast-track pathway has set a global benchmark for digital therapeutic reimbursement and is inspiring similar frameworks in other European nations. The European market is expected to grow at a CAGR of 22.5% over the 2026-2034 forecast period, driven by expanding reimbursement coverage and cross-border collaborations.

The Asia Pacific region, representing approximately 18.5% of the global market (approximately USD 331 million in 2025), is projected to exhibit the fastest growth rate during the 2026-2034 forecast period. Rising mental health awareness, increasing smartphone penetration exceeding 75% in several key markets, and supportive government mental health initiatives are key drivers of expansion in countries such as China, Japan, India, and Australia. Local startups and multinational companies are actively developing and launching culturally tailored digital therapeutic solutions to address the unique linguistic, cultural, and clinical needs of diverse populations across the region. Latin America and the Middle East & Africa collectively account for the remaining approximately 9.5% of market share in 2025, with growing investments in digital health infrastructure and shifting societal attitudes towards mental health care setting the stage for accelerated growth through 2034.

Competitor Outlook

The Digital Therapeutics for Generalized Anxiety Disorder market in 2025 is characterized by a dynamic and intensely competitive landscape, with numerous established players and innovative startups vying for market share. The competitive environment is defined by rapid technological advancement, frequent product launches, and strategic collaborations aimed at enhancing product offerings and expanding market reach. Companies are focusing on clinical validation, user engagement optimization, and regulatory compliance to differentiate themselves in a crowded marketplace. The ability to demonstrate robust clinical outcomes through randomized controlled trials and real-world evidence, combined with seamless integration with healthcare systems and intuitive user interfaces, has become a primary determinant of competitive success in 2025.

Strategic partnerships and mergers and acquisitions continue to reshape the competitive dynamics of the market. Leading technology firms are collaborating with healthcare providers, payers, and academic institutions to co-develop and commercialize digital therapeutic solutions for Generalized Anxiety Disorder. These partnerships enable companies to leverage complementary expertise, accelerate product development timelines, and navigate complex multi-jurisdictional regulatory environments. Consolidation trends are evident, with larger health systems and managed care organizations acquiring digital mental health companies to internalize capabilities and expand their service offerings. The influx of venture capital and strategic investment continues to fuel innovation and support the growth of promising early-stage companies through the forecast period.

The market is witnessing a clear trend towards the development of comprehensive digital mental health platforms that address multiple conditions simultaneously, including Generalized Anxiety Disorder, depression, insomnia, and stress. Companies are investing heavily in artificial intelligence and natural language processing to enhance personalization, conversational engagement, and adaptive treatment delivery. The integration of wearable devices, continuous biometric monitoring, and virtual reality environments is creating differentiated offerings with strong clinical narratives. Enterprise-focused companies such as Spring Health, Lyra Health, and Modern Health have secured large employer and payer contracts that provide both scale and recurring revenue, while condition-specific specialists like Big Health and Meru Health continue to advance the clinical evidence base for their focused solutions.

Key players in the Digital Therapeutics for Generalized Anxiety Disorder market include Big Health, Woebot Health, Click Therapeutics, Limbix, Meru Health, Sanvello Health (Optum), myStrength (Teladoc Health), Headspace Health, SilverCloud Health (Amwell), Happify Health, Akili Interactive, Omada Health, AbleTo (Teladoc Health), Flow Neuroscience, Healios, Calm, Spring Health, Lyra Health, Modern Health, and Noom. Big Health is recognized for its FDA-Breakthrough-designated digital CBT programs targeting anxiety and insomnia. Woebot Health leverages conversational AI to deliver accessible mental health support at scale. Click Therapeutics is advancing a pipeline of prescription digital therapeutics with rigorous clinical development programs. SilverCloud Health offers a comprehensive suite of evidence-based digital mental health programs adopted by leading health systems and payers worldwide.

In addition to these established players, the market is witnessing the continued emergence of regional and condition-specific startups developing culturally tailored solutions for previously underserved population segments. The competitive landscape is expected to remain dynamic through 2034, with ongoing innovation, strategic consolidation, regulatory developments, and evolving reimbursement policies collectively shaping the future trajectory of the Digital Therapeutics for Generalized Anxiety Disorder market globally.

Key Players

• Big Health
• Woebot Health
• Click Therapeutics
• Limbix
• Meru Health
• Sanvello Health (Optum)
• myStrength (Teladoc Health)
• Headspace Health
• SilverCloud Health (Amwell)
• Happify Health
• Akili Interactive
• Omada Health
• AbleTo (Teladoc Health)
• Flow Neuroscience
• Healios
• Calm
• Spring Health
• Lyra Health
• Modern Health
• Noom